Global Choroidal Neovascularization Therapeutics Report 2016: Pipeline Review of 8 Companies & 16 Drug Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Choroidal Neovascularization - Pipeline Review, H2 2016" report to their offering.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

Choroidal Neovascularization pipeline therapeutics constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Choroidal Neovascularization - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects.

Key Topics Covered:

1. Introduction
2. Choroidal Neovascularization Overview
3. Therapeutics Development
4. Pipeline Products for Choroidal Neovascularization - Overview
5. Pipeline Products for Choroidal Neovascularization - Comparative Analysis
6. Choroidal Neovascularization - Therapeutics under Development by Companies
7. Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes
8. Choroidal Neovascularization Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Choroidal Neovascularization - Products under Development by Companies
13. Choroidal Neovascularization - Products under Investigation by Universities/Institutes
14. Choroidal Neovascularization - Companies Involved in Therapeutics Development

• F. Hoffmann-La Roche Ltd.
• Formycon AG
• Genentech, Inc.
• Graybug Vision Inc
• Mabion SA
• Navigen Pharmaceuticals, Inc.
• Noxxon Pharma AG
• Promedior, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/ctbsxg/choroidal